Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06521476 · ClinicalTrials.gov registry record · Phase 2
Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder
A Phase 2 study of Central Sleep Apnea Comorbid With Opioid Use, sponsored by Sanjay R Patel.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06521476 is a Phase 2 study of Central Sleep Apnea Comorbid With Opioid Use that is actively recruiting participants, run by Sanjay R Patel. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06521476, a Phase 2 study of Central Sleep Apnea Comorbid With Opioid Use, is actively recruiting participants, sponsored by Sanjay R Patel.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with opioid use disorder treated with either methadone or buprenorphine are at risk of developing central sleep apnea (CSA) from these medications. Investigators will conduct a mechanistic trial using acetazolamide, a medicine known to improve CSA in other settings, to determine if acetazolamide can improve CSA due to medication for opioid use disorder and whether this leads to physiologic changes that might lead to reduced drug craving. Patients treated with medication for opioid use disorder and who have central sleep apnea will be randomized to treatment with acetazolamide or matching placebo for 7 days. At the end of the 7 days, they will undergo an overnight sleep study to assess the impact on breathing during sleep as well as sleep quality. In addition, measures of sympathetic tone, anxiety, arousal, cognition, and drug craving will be measured to determine if treatment of CSA with acetazolamide can produce physiologic changes that might contribute to improved health.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Acetazolamide
Study Locations (1)
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06521476
The ClinicalTrials.gov registry entry for NCT06521476 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanjay R Patel, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Central Sleep Apnea Comorbid With Opioid Use appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06521476 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06521476 about?
NCT06521476 is a clinical study titled "Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder". Patients with opioid use disorder treated with either methadone or buprenorphine are at risk of developing central sleep apnea (CSA) from these medications. Investigators will conduct a mechanistic trial using acetazolamide, a medicine known to improve CSA in other settings, to determine if acetazol...
What is the current status of trial NCT06521476?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-09-30. Estimated completion is 2028-02.
What conditions does trial NCT06521476 study?
This clinical trial studies the following conditions: Central Sleep Apnea Comorbid With Opioid Use.
What interventions are being tested in trial NCT06521476?
The interventions under investigation include: Placebo (DRUG), Acetazolamide (DRUG).
Who is sponsoring clinical trial NCT06521476?
This trial is sponsored by Sanjay R Patel, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06521476 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.